Endonovo Therapeutics, founded in the United States, is a commercial-stage developer specializing in non-invasive electromagnetic therapies. The company's core mission is to provide innovative medical solutions for treating inflammatory conditions, cardiovascular diseases, and central nervous system disorders. Their proprietary Electroceutical® Therapy is FDA-cleared for palliative treatment of pain and post-surgical edema and CE-marked for promoting wound healing. Endonovo focuses on both human and animal health markets, aiming to revolutionize treatment methodologies with their advanced medical devices.

Notable figures associated with Endonovo Therapeutics include key investors and board members who have significantly contributed to the company's growth. The company has achieved critical regulatory milestones, including FDA clearance and CE marking, which validate the efficacy and safety of their therapies. Endonovo's impact is evident in its innovative approach to non-invasive treatment options, offering new hope for patients with chronic and acute conditions. Their advancements in medical technology continue to influence the healthcare industry positively.